Compound: MCI-186
SMILES: O=C1N(N=C(C1)C)c2ccccc2
InChIKey: QELUYTUMUWHWMC-UHFFFAOYSA-N
Synonyms: MCI-186, MCI 186, RefChem:57584, edaravone, 89-25-8, Radicut, 3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE, Norphenazone, 1-Phenyl-3-methyl-5-pyrazolone, Developer Z, Methylphenylpyrazolone, Norantipyrine, C.I. Developer 1, Phenyl methyl pyrazolone, Phenylmethylpyrazolone, Radicava, 3-Methyl-1-phenyl-5-pyrazolone, 5-Methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one, 3-Methyl-1-phenyl-1H-pyrazol-5(4H)-one, 3-Methyl-1-phenyl-2-pyrazoline-5-one, 5-methyl-2-phenyl-4H-pyrazol-3-one, 1-Phenyl-3-methyl-5-oxo-2-pyrazoline, 3H-Pyrazol-3-one, 2,4-dihydro-5-methyl-2-phenyl-, 1-Phenyl-3-methylpyrazolone, 2-Pyrazolin-5-one, 3-methyl-1-phenyl-, 1-Phenyl-3-methylpyrazolone-5, 2,4-Dihydro-5-methyl-2-phenyl-3H-pyrazol-3-one, Edaravone (MCI-186), 3-Methyl-1-phenylpyrazol-5-one, NCI-C03952, 5-Pyrazolone, 3-methyl-1-phenyl-, MFCD00003138, Colorex pmp, Jarocol pmp, NSC-2629, 1-Fenyl-3-methyl-2-pyrazolin-5-on, NSC-26139, 3-methyl-1-phenyl-4,5-dihydro-1H-pyrazol-5-one, DTXSID9021130, 1-Phenyl-3-methyl-5-pyrazolinone, S798V6YJRP, MLS000069602, 3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE (MCI-186), CHEBI:31530, s1326, CI Developer 1, NCGC00164015-01, SMR000059020, Edaravone [INN], DTXCID201130, Monopyrazolone, WLN: T5NMV DHJ BR& E1, CAS-89-25-8, CCRIS 512, Radicut (TN), HSDB 4102, 3H-Pyrazol-3-one,4-dihydro-5-methyl-2-phenyl-, SR-01000000135, 1-Fenyl-3-methyl-2-pyrazolin-5-on [Czech], EINECS 201-891-0, UNII-S798V6YJRP, BRN 0609575, edaravona, 3-?Methyl-?1-?phenyl-?2-?pyrazolin-?5-?one(Edaravone), AI3-03557, MCI186, (Edaravone), Radicava (TN), (MCI-186), Phenazone impurity A, Edaravone (Standard), CDS1_000986, Spectrum_000267, Tocris-0786, EDARAVONE [JAN], MCI-186; Edaravone, Edaravone [USAN:INN], EDARAVONE [HSDB], EDARAVONE [USAN], Maybridge1_005738, Opera_ID_1057, Spectrum2_001574, Spectrum3_000971, Spectrum4_001091, Spectrum5_001217, NORPHENAZONE [MI], Phenazone impurity A CRS, M0687, EDARAVONE [MART.], EC 201-891-0, EDARAVONE [WHO-DD], SCHEMBL4704, BSPBio_001235, BSPBio_002601, KBioGR_000575, KBioGR_001502, KBioSS_000575, KBioSS_000747, AE-641/00371017, MLS001146878, MLS002415675, MLS006011753, DivK1c_001018, DivK1c_002026, SCHEMBL148321, SPECTRUM1503635, SPBio_001508, CHEMBL290916, orb1310644, orb3139607, SCHEMBL4099403, SCHEMBL8935505, SCHEMBL9439001, 1-pheny-3-methyl-5-pyrazolone, Edaravone (USAN/JP18/INN), EDARAVONE [ORANGE BOOK], BCBcMAP01_000127, GTPL11994, HMS503K17, HMS557M18, HY-B0099R, KBio1_001018, KBio2_000575, KBio2_000747, KBio2_003143, KBio2_003315, KBio2_005711, KBio2_005883, KBio3_001029, KBio3_001030, KBio3_001821, NSC2629, NINDS_001018, 5-Methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one (Edaravone), Bio1_000438, Bio1_000927, Bio1_001416, Bio2_000448, Bio2_000928, GLXC-05042, HMS1362M17, HMS1792M17, HMS1990M17, HMS2234M19, HMS3266F04, HMS3403M17, HMS3411L05, HMS3654L15, HMS3675L05, HMS3884A11, HMS5079B11, Pharmakon1600-01503635, DZB76567, HY-B0099, NSC26139, Tox21_112077, Tox21_201747, Tox21_302819, BDBM50200541, CCG-39352, EBC-03526, MSK000657, NSC758622, STK201315, 1-Phenyl-3-methyl-2-pyrazolin-5-on, AKOS000313817, Tox21_112077_1, AC-4745, CS-1832, DB12243, FE22642, NSC-758622, SB19128, IDI1_001018, IDI1_002203, NCGC00018218-01, NCGC00018218-02, NCGC00018218-03, NCGC00018218-04, NCGC00018218-05, NCGC00018218-06, NCGC00018218-07, NCGC00018218-08, NCGC00018218-10, NCGC00018218-11, NCGC00018218-17, NCGC00022665-02, NCGC00022665-04, NCGC00022665-05, NCGC00022665-06, NCGC00256515-01, NCGC00259296-01, ST012744, SY008808, PHENAZONE IMPURITY A [EP IMPURITY], SBI-0051836.P002, DB-002517, NS00002708, SW148216-2, 5-methyl-2-phenyl-2,4-dihydro-3-pyrazolone, EN300-16234, 3-Methyl-1-phenyl-2-pyrazoline-5-one, 99%, 4E-901, 5-methyl-2-phenyl-2,4-dihydro-pyrazol-3-one, D01552, D86209, 3-?Methyl-?1-?phenyl-?2-?pyrazolin-?5-?one, AB00375776_14, AB00375776_15, 2 4-Dihydro-5-methyl-2-phenyl-3H-pyrazol-3-one, 2,4-dihydro-2-phenyl-5-methyl-3H-pyrazol-3-one, F038216, Q335099, SR-01000000135-2, SR-01000000135-3, SR-01000000135-5, 5-Methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one #, BRD-K35458079-001-04-2, BRD-K35458079-001-12-5, BRD-K35458079-001-23-2, BRD-K35458079-001-27-3, BRD-K35458079-001-28-1, BRD-K35458079-001-29-9, BRD-K35458079-001-31-5, BRD-K35458079-001-33-1, Z50145861, F0391-0021, 3-Methyl-1-phenyl-2-pyrazoline-5-one, SAJ special grade, 3-Methyl-1-phenyl-2-pyrazoline-5-one, purum, >=98.0% (NT), Phenazone impurity A, European Pharmacopoeia (EP) Reference Standard, InChI=1/C10H10N2O/c1-8-7-10(13)12(11-8)9-5-3-2-4-6-9/h2-6H,7H2,1H
Theoretical properties:
molecular_formula: C10H10N2O
molecular_weight: 174.20 g/mol
exact_mass: 174.079312947 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 0
hydrogen_bond_acceptor_count: 2
rotatable_bond_count: 1
heavy_atom_count: 13
topological_polar_surface_area: 32.7 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
physical_state: MONOCLINIC PRISMS FROM WATER
color: MONOCLINIC PRISMS FROM WATER
boiling_point: 549 °F at 105 mmHg (NTP, 1992)
melting_point: 261 to 266 °F (NTP, 1992)
solubility: less than 1 mg/mL at 73 °F (NTP, 1992)
vapor_pressure: less than 0.01 mmHg at 68 °F (NTP, 1992)
Descriptions:
pubchem: Edaravone is a pyrazolone that is 2,4-dihydro-3H-pyrazol-3-one which is substituted at positions 2 and 5 by phenyl and methyl groups, respectively. It has a role as an antioxidant and a radical scavenger.
chebi: A pyrazolone that is 2,4-dihydro-3H-pyrazol-3-one which is substituted at positions 2 and 5 by phenyl and methyl groups, respectively.
chembl: EDARAVONE is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Edaravone, sold under the brand name Radicava among others, is a medication used to treat stroke and amyotrophic lateral sclerosis (ALS). It is given by intravenous infusion and by mouth.
The mechanism by which edaravone might be effective is unknown. The medication is known to be an antioxidant, and oxidative stress has been hypothesized to be part of the process that kills neurons in people with ALS and in stroke victims.
The most common side effects include bruising (contusions), problems walking (gait disturbances), and headaches.
The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.